These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30845818)

  • 1. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
    Potkin SG; Kunovac J; Silverman BL; Simmons A; Jiang Y; DiPetrillo L; McDonnell D
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
    Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
    Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
    Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D
    CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
    Faden J; Serdenes R; Citrome L
    Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
    Sun L; McDonnell D; Yu M; Kumar V; von Moltke L
    Clin Drug Investig; 2019 May; 39(5):477-484. PubMed ID: 30888624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
    Kahn RS; Silverman BL; DiPetrillo L; Graham C; Jiang Y; Yin J; Simmons A; Bhupathi V; Yu B; Yagoda S; Hopkinson C; McDonnell D
    Schizophr Res; 2021 Jun; 232():45-53. PubMed ID: 34015555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
    Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
    J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
    Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
    CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
    Brunette MF; Correll CU; O'Malley SS; McDonnell D; DiPetrillo L; Jiang Y; Simmons A; Silverman BL; Citrome L; Green AI
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32160422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
    Gao J; Li J; Lu X; Yang J
    Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.
    Kahn RS; Kane JM; Correll CU; Arevalo C; Simmons A; Graham C; Yagoda S; Hu B; McDonnell D
    J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36946605
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
    Sun L; Yagoda S; Yao B; Graham C; von Moltke L
    Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
    Pathak S; Vince B; Kelsh D; Setnik B; Nangia N; DiPetrillo L; Puhl MD; Sun L; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):218-228. PubMed ID: 30476361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.